291 related articles for article (PubMed ID: 35193793)
1. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
Ismail AlHosani F; Eduardo Stanciole A; Aden B; Timoshkin A; Najim O; Abbas Zaher W; AlSayedsaleh AlDhaheri F; Al Mazrouie S; Rizvi TA; Mustafa F
Vaccine; 2022 Mar; 40(13):2003-2010. PubMed ID: 35193793
[TBL] [Abstract][Full Text] [Related]
2. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
[TBL] [Abstract][Full Text] [Related]
3. The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates.
Al Kaabi N; Oulhaj A; Al Hosani FI; Al Mazrouei S; Najim O; Hussein SE; Abdalla JS; Fasihuddin MS; Hassan AA; Elghazali G; Al Rumaithi A; Al Azazi J; Weber S; Beiram R; Parekh KA; Sheek-Hussein M; Yang Y; Xiaoming Y; Quliang J; Eltantawy I; Mahmoud S; Koshy A; Xiao P; Ganesan S; Elamin W; Zaher W
Sci Rep; 2022 Jan; 12(1):490. PubMed ID: 35017530
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates.
Al Kaabi N; Oulhaj A; Ganesan S; Al Hosani FI; Najim O; Ibrahim H; Acuna J; Alsuwaidi AR; Kamour AM; Alzaabi A; Al Shehhi BA; Al Safar H; Hussein SE; Abdalla JS; Al Mansoori DSN; Al Hammadi AAK; Amari MA; Al Romaithi AK; Weber S; Elavalli S; Eltantawy I; Alghaithi NK; Al Azazi JN; Holt SG; Mostafa M; Halwani R; Khalak H; Elamin W; Beiram R; Zaher W
Nat Commun; 2022 Jun; 13(1):3215. PubMed ID: 35680857
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
Theresa Pool SN; Shroff EH; Chetty A; Lewis L; Nonhlanhla YZ; Abdool Karim SS
PLoS One; 2024; 19(4):e0299747. PubMed ID: 38578809
[TBL] [Abstract][Full Text] [Related]
6. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang W; Zhang W; Li N; Xie Z; Zhu X; Ding L; You W; Zhao Y; Zhao J; Huang L; Shi X; Yang Y; Xu G; Wang W; Liu P; Ma M; Qiao Y; Zhao S; Chai J; Li Q; Fu H; Xu Y; Zheng X; Guo W; Yang X
Lancet Infect Dis; 2022 Feb; 22(2):196-208. PubMed ID: 34536349
[TBL] [Abstract][Full Text] [Related]
8. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.
Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R
PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077
[TBL] [Abstract][Full Text] [Related]
9. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C
Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473
[TBL] [Abstract][Full Text] [Related]
11. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.
Badano MN; Sabbione F; Keitelman I; Pereson M; Aloisi N; Colado A; Ramos MV; Ortiz Wilczyñski JM; Pozner RG; Castillo L; Wigdorovitz G; E de Bracco MM; Fink S; Chuit R; Baré P
Mol Immunol; 2022 Mar; 143():94-99. PubMed ID: 35091231
[TBL] [Abstract][Full Text] [Related]
12. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.
Mahmoud S; Ganesan S; Al Kaabi N; Naik S; Elavalli S; Gopinath P; Ali AM; Bazzi L; Warren K; Zaher WA; Hosani FA
J Clin Virol; 2022 Jun; 150-151():105161. PubMed ID: 35439702
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
Anvari E; Ghamar Talepoor A; Eshkevar Vakili M; Karimi N; Ataollahi M; Najafi G; Kabelitz D; Ahmadi I; Kalantar K
Iran J Immunol; 2022 Sep; 19(3):321-329. PubMed ID: 36190385
[TBL] [Abstract][Full Text] [Related]
14. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
Park S; Gatchalian KK; Oh H
Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Sinopharm's BBIBP-CorV Booster Vaccination against COVID-19-Related Severe and Critical Cases and Deaths in Morocco during the Omicron Wave.
Belayachi J; Mhayi A; Majidi H; El Fahime E; Abouqal R
Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543878
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates.
Dash NR; Barqawi HJ; Obaideen AA; Al Chame HQ; Samara KA; Qadri R; Eldesouki S
J Epidemiol Glob Health; 2023 Mar; 13(1):67-90. PubMed ID: 36795274
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021.
Silva-Valencia J; Soto-Becerra P; Escobar-Agreda S; Fernandez-Navarro M; Moscoso-Porras M; Solari L; Mayta-Tristán P
Travel Med Infect Dis; 2023; 53():102565. PubMed ID: 36933851
[TBL] [Abstract][Full Text] [Related]
18. Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity.
Sedaghat N; Etemadifar M; Lotfi N; Sayahi F; Chitsaz A; Salari M; Ghasemi Movaghar A
Front Immunol; 2023; 14():952911. PubMed ID: 36895555
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study.
Barzegar M; Manteghinejad A; Afshari-Safavi A; Mirmosayyeb O; Nasirian M; Bagherieh S; Mazaheri S; Rahimi M; Zabeti A; Javanmard SH; Shaygannejad V
Mult Scler Relat Disord; 2023 Mar; 71():104548. PubMed ID: 36827877
[TBL] [Abstract][Full Text] [Related]
20. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B
Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
